To find a cure for your outbreaks of pimples is not that hard task. The optimal solution is getting one that works for your specific skin type, specificity of acne outbreaks and is at the same time is natural. There are some tricks to cure acne naturally that you can use at home. There are several know types of treatments for blemishes and to apply them is a simple job. So let’s start with blackheads. One treatment for blackheads is a wash of lime and milk. What you can do is bring the milk to a gentle boil, and then add the juice from one lime. Wait till cools and you can wash your face. Another type of acne natural cure is to use an astringent for a deep cleaning of your pores. Buy a leafy mango, boil it in some water, cool it and then rub it on your face. It’s an acne natural cure that will clean your pores thoroughly.
Sounds funny, but you can use something that you probably eat everyday in some form to cure acne naturally. A raw potato is an ideal acne natural cure, especially for whiteheads. The potato has an acid in it too that scrubs away dead or dying skin cells on your face, which works as an acne natural cure. It contains and vitamin C, which gives the skin a healthy glow, and its alkaline gets rid of the bacteria. More “exotic” alternative to potatoes is papaya – you can use the fruit on your face, but it needs to be raw. An acne natural cure with these types of applications will help your skin stay healthy by stopping infection from spreading.
Finally, keep in mind that acne remedy might leave your skin a little parched for moisture at times during treatments. To re-hydrate your skin after using an acne natural cure is to use Almond Oil. Buttermilk is another way to treat skin for dryness, and so are curds. You can find a treatment solution in an acne natural cure, but take your time, and find out what works for you.
Cause
The yellow fever virus, an arbovirus of the Flavivirus genus.
Transmission
Yellow fever in urban and some rural areas is transmitted by the bite of infective Aedes aegypti mosquitoes and by other mosquitoes in the forests of South America. The mosquitoes bite during daylight hours. Transmission can occur at altitudes up to 2300 metres. Yellow fever virus infects humans and monkeys.
In jungle and forest areas, monkeys are the main reservoir of infection, with transmission from monkey to monkey carried out by mosquitoes. The infective mosquitoes may bite humans who enter the forest area, usually causing sporadic cases or small outbreaks.
In urban areas, monkeys are not usually involved and infection is transmitted among humans by mosquitoes. Introduction of infection into densely populated urban areas can lead to large epidemics of yellow fever.
In Africa, an intermediate pattern of transmission is common in humid savannah regions. Mosquitoes infect both monkeys and humans, causing localized outbreaks.
Nature of the disease
Although most of the infections are asymptomatic and not detected, some infections lead to an acute illness characterized by two phases. Initially, there is fever, muscular pain, headache, chills, anorexia, nausea and/or vomiting, often with bradycardia. About 15% of patients progress to a second phase after a few days, with resurgence of fever, development of jaundice, abdominal pain, vomiting and haemorrhagic manifestations; half of these patients die 10–14 days after onset of illness.
Geographical distribution
The yellow fever virus is endemic in some tropical areas of Africa and central and South America. The number of epidemics has increased since the early 1980s. Other countries are considered to be at risk of introduction of yellow fever due to the presence of the vector and suitable primate hosts (including Asia, where yellow fever has never been reported).
Risk for travellers
The normally low risk to travellers increases with travel to jungle areas in endemic countries and in or near cities during urban outbreaks. Areas where yellow fever virus is present far exceed those offi cially reported. The risk of exposure to infection can be reduced by taking measures to prevent mosquito bites (see Chapter 3). It should be noted that the mosquito vectors of yellow fever bite mostly during daylight hours. Although reported cases of human disease are the principal indicator of disease risk, some countries may have no reported cases, either because of a high level of vaccine coverage against yellow fever in the population or because poor surveillance resulted in no cases being reported. However, the risk of yellow fever may still persist as the virus, the vector or the animal reservoir is still present.
Vaccine
The 17D vaccine, which is based on a live, attenuated viral strain, is the only commercially available yellow fever vaccine. It is given as a single subcutaneous (or intramuscular) injection. Yellow fever vaccine is highly effective (approaching 100%), while the disease may be fatal in adults who are not immune. With few exceptions (see below), vaccination is recommended for all travellers to countries or areas where there is a risk of yellow fever transmission (see country list and Annex 1).
Precautions and contraindications
Tolerance of the vaccine is generally excellent – only 2–5% of vaccine recipients have mild reactions, including myalgia and headache. Contraindications include true allergy to egg protein, cellular immunodefi ciency (congenital or acquired, the latter sometimes being only temporary) and symptomatic HIV infection. Many industrialized countries administer yellow fever vaccine to persons with symptomatic HIV infection provided that the CD4 count is at least 200 cells/ mm3. Asymptomatic HIV-positive individuals may have a reduced response to the vaccine. There is a theoretical risk of harm to the fetus if the vaccine is given during pregnancy, but this must be weighed against the risk to the mother of remaining unvaccinated and travelling to a high-risk zone. (However, pregnant women should be advised not to travel to areas where exposure to yellow fever may occur.) Encephalitis has been reported as a rare event following vaccination of infants under 9 months of age; as a result, the vaccine is contraindicated in children aged under 6 months and is not recommended for those aged 6–8 months. There have been recent reports of a small number of serious adverse events (including deaths), of vaccine-associated viscerotropic disease, following immunization with the yellow fever 17DD vaccine. The evidence suggests that the incidence of adverse events may be different in regions where yellow fever is endemic (from 0 to 0.21 per 100 000 doses) and in regions with populations not exposed to the virus (from 0.09 to 0.4 per 100 000 doses). The risk of adverse events may be related to population differences (e.g. previous vaccination or exposure to wild yellow fever virus). This risk appears to be limited to the fi rst immunization. Also recently identifi ed as potential risk factors are a history of thymus disease (e.g. thymoma) and age over 60. Adverse events of vaccine-associated neurotropic disease have been reported (e.g. meningoencephalitis, acute disseminated encephalomyelitis and Guillain-Barré syndrome). The incidence rate reported in travellers from the United States and Europe ranges between 0.19 to 0.8 per 100 000 doses. The risk to unvaccinated individuals who visit countries where there may be yellow fever transmission is far greater than the risk of a vaccine-related adverse event, and it remains important for all travellers at risk to be vaccinated. Nonetheless, great care should be exercised not to prescribe yellow fever vaccination to individuals who are not at risk of exposure to infection, based on an accurate assessment of the travel itinerary. Yellow fever vaccination should be encouraged as a key prevention strategy, but it is important to screen travel itineraries, particularly of older travellers, and carefully evaluate the potential risk of systemic illness after yellow fever vaccination.
Type of vaccine: Live, attenuated Number of doses:One priming dose of 0.5 ml Booster:10-yearly (if re-certification is needed) Contraindications:Egg allergy; immunodeficiency from medication, disease or symptomatic HIV infection; hypersensitivity to a previous dose; pregnancy (see text above) Adverse reactions:Rarely, encephalitis or hepatic failure Before departure:International certificate of vaccination becomes valid 10 days after vaccination Recommended for: All travellers to areas with risk of yellow fever transmission and wherever mandatory Special precautions:Not for infants under 9 months of age; restrictions in pregnancy
Cause
Salmonella typhi, the typhoid bacillus, which infects only humans. Similar paratyphoid and enteric fevers are caused by other species of Salmonella, which infect domestic animals as well as humans.
Transmission
Infection is transmitted by consumption of contaminated food or water. Occasionally direct faecal–oral transmission may occur. Shellfish taken from sewage-polluted beds are an important source of infection. Infection occurs through eating fruit and vegetables fertilized by night soil and eaten raw, and milk and milk products that have been contaminated by those in contact with them. Flies may transfer infection to foods, resulting in contamination that may be sufficient to cause human infection. Pollution of water sources may produce epidemics of typhoid fever, when large numbers of people use the same source of drinking-water.
Nature of the disease
A systemic disease of varying severity. Severe cases are characterized by gradual onset of fever, headache, malaise, anorexia and insomnia. Constipation is more common than diarrhoea in adults and older children. Without treatment, the disease progresses with sustained fever, bradycardia, hepatosplenomegaly, abdominal symptoms and, in some cases, pneumonia. In white-skinned patients, pink spots (papules), which fade on pressure, appear on the skin of the trunk in up to 50% of cases. In the third week, untreated cases develop additional gastrointestinal and other complications, which may prove fatal. Around 2–5% of those who contract typhoid fever become chronic carriers, as bacteria persist in the biliary tract after symptoms have resolved.
Geographical distribution
Worldwide. The disease occurs most commonly in association with poor standards of hygiene in food preparation and handling and where sanitary disposal of sewage is lacking.
Risk for travellers
All travellers to endemic areas are at potential risk of typhoid fever, although the risk is generally low in tourist and business centres where standards of accommodation, sanitation and food hygiene are high. The risk is particularly high in the Indian subcontinent. Even vaccinated individuals should take care to avoid consumption of potentially contaminated food and water as the vaccine does not confer 100% protection.
Vaccine
Travellers to countries where the risk of typhoid fever is high, where hygiene is poor, and where there is a high prevalence of antibiotic-resistant organisms, may be offered one of the following vaccines.
Oral Ty21a. This live, attenuated mutant strain of Salmonella typhi Ty21a, supplied as enteric coated capsules, is given orally in three doses (four in North America) 2 days apart, and produces protection 7 days after the fi nal dose. Seven years after the fi nal dose the protective effi cacy is 67% in residents of endemic areas but may be less for travellers. A liquid formulation is no longer available.
Injectable Vi CPS. Capsular Vi polysaccharide vaccine (Vi CPS), containing 25 µg of polysaccharide per dose, is given i.m. in a single dose and produces protection 7 days after injection. In endemic areas, the protective effi cacy after vaccination is 72% after 1.5 years and 50% after 3 years.
Both vaccines are safe and effective. However, their effi cacy in children under 2 years of age has not been demonstrated.
A combined typhoid/hepatitis A vaccine is also available in some countries.
Precautions and contraindications
Proguanil, mefl oquine and antibiotics should be stopped from 3 days before until 3 days after giving Ty21a.
No serious adverse effects have been reported following administration of Ty 21a or Vi CPS.
These vaccines are not recommended for use in infant immunization programmes:
there is insufficient information on their effi cacy in children under 2 years of age.
Type of vaccine:Oral Ty21a and injectable Vi CPS Number of doses:One of Vi CPS, i.m. Three or four of live Ty21a, given orally at 2-day intervals as enteric coated capsule Booster:Every 2 to 3 years for Vi CPS; for Ty21a see package inserta Contraindications:Proguanil, mefloquine and antibiotics 3 days before or after starting Ty21a Adverse reactions:None significant Before departure:1 week Recommended for:Travellers to high-risk areas and travellers staying longer than 1 month or likely to consume food or beverages away from the usual tourist routes in developing countries Special precautions:Vi CPS – not under 2 years of age; avoid proguanil, mefloquine and antibiotics with Ty21a
There are several know types of treatments for blemishes and to apply them is a simple job. So let’s start with blackheads. One treatment for blackheads is a wash of lime and milk. What you can do is bring the milk to a gentle boil, and then add the juice from one lime. Wait till cools and you can wash your face. Another type of acne natural cure is to use an astringent for a deep cleaning of your pores. Buy a leafy mango, boil it in some water, cool it and then rub it on your face. It’s an acne natural cure that will clean your pores thoroughly.